← Back to headlines
Biohaven Completes Enrollment for Phase 2 Obesity Drug Study
Biohaven Pharmaceuticals has announced the completion of enrollment for its Phase 2 clinical study of taldefgrobep alfa, an investigational drug for obesity.
27 Mar, 07:29 — 27 Mar, 07:29
Sources
Showing 1 of 1 sources
